Page 14 - Ioscience News Today

New York, New York--(Newsfile Corp. - November 21, 2022) - PCG Digital -- Lexaria Bioscience (NASDAQ: LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against

Mito Plus was launched during the Bengaluru Tech Summit, which is being held between 16th and 18th November 2022.

Item 2.02Results of Operations and Financial Condition. On November 18, 2022, Twist Bioscience Corporation issued a press release announcing its financial results for the fourth quarter and... | November 18, 2022

Establishes first-in-class biopharmaceutical commercialization platform specifically addressing rare diseases in Europe Secured exclusive rights in 26 European Countries to an investigational

KELOWNA, BC / ACCESSWIRE / November 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program

DJ Unaudited NAV for October 2022 Arix Bioscience PLC (ARIX) Unaudited NAV for October 2022 09-Nov-2022 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer

KELOWNA, BC / ACCESSWIRE / November 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program

Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction Vancouver, British Columbia--(Newsfile Corp. - November 7, 2022) - Emerald Health Therapeutics, Inc.

HONG KONG, Nov 4, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical

-Proof of concept studies to be completed by YE- Toronto, Ontario--(Newsfile Corp. - November 3, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company developing